logo
Inovalis Real Estate Investment Trust Announces the Financial Results for Q1 2025

Inovalis Real Estate Investment Trust Announces the Financial Results for Q1 2025

National Post13-05-2025

Article content
TORONTO — Inovalis Real Estate Investment Trust (the 'REIT') (TSX: INO.UN) today reported financial results for the quarter ended March 31, 2025. The unaudited Consolidated Financial Statements and Management's Discussion and Analysis ('MD&A') for Q1 2025 are available on the REIT's website at www.inovalisreit.com and at www.sedarplus.ca. All amounts except rental rates, square footage and per unit amounts are presented in thousands of Canadian dollars or Euros, or as otherwise stated.
Article content
Article content
Stephane Amine, CEO and President of the REIT, commented, ' The recent Sablière sale, completed at a price near our market cap, highlights the value embedded in our portfolio and our disciplined execution. As we pursue further dispositions, we are strategically reshaping the portfolio in response to enduring changes in how and where people work. '
Article content
Net Rental Income
Article content
For the portfolio that includes assets owned entirely by the REIT ('IP Portfolio'), Net Rental Income ('NRI') for Q1 2025 decreased to $155 (€103), compared to the $912 (€623) NRI for Q1 2024, notably caused by the vacancies at the Bad Homburg and the Metropolitain properties.
Article content
In Q1 2025, Net Rental Income, adjusted for IFRIC 21 1 for the portfolio that includes the REIT's proportionate share in joint ventures ('Total Portfolio'), was $5,000 (€3,310), compared to $6,548 (€4,473) for Q1 2024, a decrease related to the vacancies at Bad Homburg and Metropolitain, added to the non-recurring $1,058 indemnity obtained on the Duisburg property related to the early departure of a tenant in Q1 2024.
Article content
Leasing Operations
Article content
As of March 31, 2025, the occupancy rate of the REIT's IP Portfolio was 47.1% and the occupancy rate of the REIT's Total Portfolio was 58.9%. Strategic vacancies are being maintained in the Arcueil and Baldi properties in support of planned redevelopment or disposition initiatives as outlined in the Asset Recycling Plan. Excluding properties designated for asset recycling, the Total Portfolio occupancy rate was 81.3%.
Article content
During the first quarter of 2025, a lease was reduced by 60% and extended for 3 years at the Trio property.
Article content
Momentum from increased tenant interest in the second half of 2024 carried into early 2025, resulting in executed leases and ongoing positive negotiations—particularly in the vacancies at the Neu-Isenburg property.
Article content
To support leasing activity, management continues to collaborate with on-site brokers and is selectively evaluating tenant improvement allowances as a means to enhance the competitiveness of key assets and optimize rental income.
Article content
Asset Recycling Plan
Article content
Subsequent to quarter-end, on April 30, 2025, the REIT completed the sale of the Sablière property, located in downtown Paris, for €18,200 ($28,323), as part of its Asset Recycling Plan. This transaction aligns with the REIT's strategic objectives of repositioning the portfolio and strengthening financial flexibility. Net proceeds of approximately $13 million (€8.4 million) will be allocated toward debt reduction and reinvestment in value-enhancing initiatives across the portfolio.
Article content
An exchange contract confirming the sale of 87.5% of the Arcueil property for €37,540 ($58,420) was announced in January 2025 with closing expected in the second half of 2026. The long closing is required to satisfy the administrative, building permit and financing conditions. The remaining 12.5% of the Arcueil office property is being marketed for a new office tenant.
Article content
The Baldi property, with a fair value of $27,534 (€17,400), is currently being marketed for sale under the REIT's Asset Recycling Plan. The REIT is currently evaluating offers that are not subject to building permit conditions, which may result in a disposition prior to year-end 2025.
Article content
As the REIT generates revenue from the sale of properties, the best use of the proceeds will be considered, including the options to pay down debt, invest capital to support leasing or redevelopment opportunities.
Article content
Since the end of 2023, net asset values for the REITs Total Portfolio have been significantly pressured, primarily due to geopolitical tensions, high inflation, high interest rates and energy costs. The decrease in net asset values largely impacted Unitholders' equity that was $192,775 (€123,875) at March 31, 2025. The book value per Unit at March 31, 2025 was $5.81/Unit and $5.75/Unit on a fully-diluted basis, using the weighted average number of units of the REIT (the 'Units') for the period. The closing price of a Unit on the TSX at March 31, 2025 was $0.90/Unit.
Article content
The REIT has addressed the volatile risks in the current capital markets by selling certain properties, implementing short term leasing initiatives for properties in the REIT's Asset Recycling Plan, maintaining a manageable debt-to-gross-book value ratio, currently 51.3% of the IP Portfolio (58.8% on the Total Portfolio).
Article content
FFO per Unit of $0.01 and AFFO 1 per Unit of $0.02 were reported for Q1 2025, in line with our projection given the occupancy rate and increased cost of debt. Refer to the 'Financing Activity' section below for details of the impact of finance costs on FFO and AFFO.
Article content
The REIT is financed almost exclusively with asset-level, non-recourse financing with an average term to maturity of 2.4 years for the Total Portfolio (2.7 years for the IP Portfolio).
Article content
For the three-month period ended March 31, 2025, the weighted average interest rate across the Total Portfolio declined to 3.43%, from 4.12% as at December 31, 2024, reflecting the downward trend in EURIBOR. As at March 31, 2025, 72% of the REIT's Total Portfolio debt was subject to variable interest rates, primarily associated with short-term financing on properties currently being marketed for sale.
Article content
On March 19, 2025, HCOB, the senior lender for the Trio property, approved a six month extension of the loan facility to September 2025, subject to a partial repayment of $8,559 that should be completed on May 15, 2025. This repayment will satisfy a waiver condition related to a second-ranking mortgage held by HCOB on the Bad Homburg property.
Article content
The Trio loan repayment is funded by a €5,600 ($8,715) mezzanine loan on the Bad Homburg property, signed on April 16, 2025. The 18-month mezzanine loan bears annual interest at 12% (6% paid quarterly and 6% at maturity). Management's objective is to eventually refinance this loan with a conventional financing, depending on progress in the leasing strategy.
Article content
Integration of ESG objectives and strategies into the REIT's business reflects the growing importance of these factors among many of our key stakeholders. The REIT is working to improve its long-term environmental performance, and also to invest in 'human capital' for the implementation and monitoring of all ESG initiatives.
Article content
Certain statements contained, or contained in documents incorporated by reference, may constitute forward-looking information within the meaning of securities laws. Forward-looking information may relate to the REIT's future outlook and anticipated events or results and may include statements regarding the future financial position, business strategy, budgets, occupancy rates, rental rates, productivity, projected costs, capital investments, development and development opportunities, financial results, taxes, plans and objectives of or involving the REIT. Particularly, statements regarding the REIT's future results, performance, achievements, prospects, costs, opportunities, and financial outlook, including those relating to the sale of the Arcueil property, acquisition and capital investment strategies and the real estate industry generally, are forward-looking statements. In some cases, forward-looking information can be identified by terms such as 'may', 'will', 'should', 'expect', 'plan', 'anticipate', 'believe', 'intend', 'estimate', 'predict', 'potential', 'continue' or the negative thereof, or other similar expressions concerning matters that are not historical facts. Forward-looking statements are based on certain factors and assumptions regarding expected growth, results of operations, performance, and business prospects and opportunities.
Article content
Although management believes that the expectations reflected in the forward-looking information are reasonable, no assurance can be given that these expectations will prove to be correct, and since forward-looking information inherently involves risks and uncertainties, undue reliance should not be placed on such information.
Article content
Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such forward-looking statements. The estimates and assumptions, which may prove to be incorrect, include, but are not limited to, the various assumptions set forth in this press release as well as the following:
Article content
(i)
the ability to complete the sale of the Arcueil property;
(ii)
the ability to continue to receive financing on acceptable terms;
(iii)
the future level of indebtedness and the REIT's future growth potential will remain consistent with current expectations;
(iv)
there will be no changes to tax laws adversely affecting the REIT's financing capability, operations, activities, structure, or distributions;
(v)
the REIT will retain and continue to attract qualified and knowledgeable personnel as the portfolio and business grow;
(vi)
the impact of the current economic climate and the current global financial conditions on operations, including the REIT's financing capability and asset value, will remain consistent with current expectations;
(vii)
there will be no material changes to government and environmental regulations that could adversely affect operations;
(viii)
conditions in the international and, in particular, the French, German, Spanish and other European real estate markets, including competition for acquisitions, will be consistent with past conditions; and
(ix)
the demand for the REIT's properties and global supply chains and economic activity in general.
Article content
The REIT cautions that this list of assumptions is not exhaustive. Although the forward-looking statements contained in this press release are based upon assumptions that management believes are reasonable based on information currently available to management, there can be no assurance that actual results will be consistent with these forward-looking statements.
Article content
When relying on forward-looking statements to make decisions, the REIT cautions readers not to place undue reliance on these statements, as forward-looking statements involve significant risks and uncertainties. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not, or the times at or by which, such performance or results will be achieved. A number of factors could cause actual results to differ, possibly materially, from the results discussed in the forward-looking statements, including, but not limited to:
Article content
the REIT's ability to execute its growth and capital deployment strategies;
the impact of changing conditions in the European office market;
the marketability and value of the REIT's portfolio;
changes in the attitudes, financial condition and demand in the REIT's demographic markets;
fluctuation in interest rates and volatility in financial markets;
the geopolitical conflict around the world on the REIT's business, operations and financial results;
general economic conditions, including any continuation or intensification of the current economic conditions;
developments and changes in applicable laws and regulations; and
such other factors discussed under ''Risk and Uncertainties'' in the MD&A dated September 30, 2024 ('the MD&A').
Article content
If any risks or uncertainties with respect to the above materialize, or if the opinions, estimates or assumptions underlying the forward-looking statements prove incorrect, actual results or future events might vary materially from those anticipated in the forward-looking statements. The opinions, estimates or assumptions referred to above and described in greater detail under ''Risks and Uncertainties'' in the MD&A should be considered carefully by readers. Although management has attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other risk factors not presently known or that management believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking statements.
Article content
Forward-looking statements are provided for the purpose of providing information about management's current expectations and plans relating to the future. Certain statements included in press release may be considered a ''financial outlook'' for purposes of applicable Canadian securities laws, and as such, the financial outlook may not be appropriate for purposes other than this press release. All forward-looking statements are based only on information currently available to the REIT and are made as of the date of this press release. Except as expressly required by applicable Canadian securities law, the REIT assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements in this press release are qualified by these cautionary statements.
Article content
There are financial measures included in this MD&A that do not have a standardized meaning under IFRS. These measures include Funds from Operations, Adjusted Funds from Operations, and other measures presented on a proportionate share basis. These measures have been derived from the REIT's financial statements and applied on a consistent basis as appropriate. Management includes these measures as they represent key performance indicators to management, and it believes certain investors use these measures as a means of assessing relative financial performance. These measures, as computed by the REIT, may differ from similar computations as reported by other entities and, accordingly, may not be comparable to other such entities. These measures should not be considered in isolation or used in substitute for other measures of performance prepared in accordance with IFRS.
Article content
USE OF OPERATING METRICS
Article content
The REIT uses certain operating metrics to monitor and measure the operational performance of its portfolio. Operating metrics in this press release include GLA, committed occupancy, Weighted Average Lease Term and average term to maturity. Certain of these operating metrics, may constitute supplementary financial measures as defined in National Instrument 52-112 – Non-GAAP and Other Financial Measures Disclosure. These supplementary measures are not derived from directly comparable measures contained in the REIT's financial statements but may be used by management and disclosed on a periodic basis to depict the historical or future expected financial performance, financial position or cash flow of the REIT.
Article content
' Adjusted Funds From Operations ' or ' AFFO ' is a meaningful supplemental measure that can be used to determine the REIT's ability to service debt, fund expansion capital expenditures, fund property development, and provide distributions to Unitholders after considering costs associated with sustaining operating earnings.
Article content
AFFO calculations are reconciled to net income, which is the most directly comparable IFRS measure. AFFO should not be construed as an alternative to net income or cash flow generated from operating activities, determined in accordance with IFRS.
Article content
AFFO is defined as FFO subject to certain adjustments, including adjustments for: (i) the non-cash effect of straight-line rents, (ii) the cash effect of the rental guarantee received, (iii) amortization of fair value adjustment on assumed debt, (iv) capital expenditures, excluding those funded by a dedicated cash reserve or capex financing, and (v) amortization of transaction costs on mortgage loans.
Article content
' Adjusted Funds From Operations / Unit ' or ' AFFO / Unit ' is AFFO divided by the issued and outstanding Units, plus Exchangeable Securities (fully diluted basis).
Article content
' AFFO Payout Ratio ' is the value of declared distributions on Units and Exchangeable Securities, divided by AFFO.
Article content
' Average term to maturity ' refers to the average number of years remaining in the lease term.
Article content
' Book value per Unit ' refers to the REIT's total equity divided by the Weighted Average number of Units and Exchangeable Securities (on a fully diluted basis).
Article content
'Debt-service covenant ratio calculation' or 'DSCR' refers to the rental income divided by the debt service, including interest and amortization.
Article content
' Debt-to-Gross-Book Value ' refers to the REIT's apportioned amount of indebtedness respectively in the IP Portfolio and the Total Portfolio. Indebtedness on an IP and Total Portfolio basis is calculated as the sum of (i) lease liabilities, (ii) mortgage loans, (iii) other long-term liabilities, and (iv) deferred tax liabilities. Indebtedness does not include certain liabilities as is the case for the Exchangeable Securities and at the joint venture level for the contribution from the REIT and its partners.
Article content
' Exchangeable Securities ' means the exchangeable securities issued by CanCorpEurope, in the form of interest bearing notes, non-interest bearing notes and variable share capital.
Article content
' Fully diluted basis ' refers to a nominal value divided by the issued and outstanding Units, plus Exchangeable Securities.
Article content
' Funds From Operations ' or ' FFO' follows the definition prescribed by the Real Estate Property Association of Canada publication on Funds From Operations & Adjusted Funds From Operations, dated January 2023 with one exception.
Article content
Management considers FFO to be a meaningful supplemental measure that can be used to determine the REIT's ability to service debt, fund capital expenditures, and provide distributions to Unitholders.
Article content
As an exception, considering the significant amount of cash held in Euros in Canada and the volatility of the Canadian dollar against the Euro, the unrealized gain (loss) recognized for the three and twelve months ended December 31, 2024, and 2023, have been excluded from the FFO calculation. Finally, non-recurring administrative expenses relating to items that are not reasonably likely to occur within two years prior to, or following the disclosure, have also been excluded from FFO.
Article content
FFO is reconciled to net income, which is the most directly comparable IFRS measure. FFO should not be construed as an alternative to net income or cash flow generated from operating activities, determined in accordance with IFRS.
Article content
FFO for the REIT is defined as net income in accordance with IFRS, subject to certain adjustments including adjustments for: (i) acquisition, eviction and disposal costs (if any), (ii) net change in fair value of investment properties, (iii) net change in fair value of derivative financial instruments at fair value through profit and loss, (iv) net changes in fair value of Exchangeable Securities, (v) finance costs related to distribution on Exchangeable Securities, (vi) adjustment for property taxes accounted for under IFRIC 21 (if any), (vii) loss on exercise of lease option (if any), (viii) adjustment for foreign exchange gains or losses on monetary items not forming part of an investment in a foreign operation (if any), (ix) gain or loss on disposal of investment properties or an interest in a subsidiary (if any), (x) finance income earned from loans to joint ventures (if any), (xi) loss on extinguishment of loans (if any), (xii) deferred taxes, (xiii) non-controlling interest, (xiv) goodwill / bargain purchase gains upon acquisition, and (xv) income taxes on sale of investment properties and provision for tax reassessment.
Article content
Exchangeable Securities are recorded as liabilities. Exchangeable Securities are recorded at fair value through profit and loss in accordance with IFRS. However, both are considered as equity for the purposes of calculating FFO and AFFO, as they are economically equivalent to the REIT's Units, with the same features and distribution rights, that are economically equivalent to the distribution received by Unitholders.
Article content
' Funds From Operations / Unit ' or ' FFO / Unit ' is FFO divided by the issued and outstanding Units, plus Exchangeable Securities (fully diluted basis).
Article content
' Gross book value ' refers to the total consolidated assets for the IP Portfolio and Total Portfolio.
Article content
'Interest Coverage Ratio' or 'ICR' covenant refers to a financial metric used to assess a REIT's ability to meet its interest obligations on outstanding debt. It indicates how many times the operating profit can cover the REIT's interest expenses over a given period.
Article content
' Investments in Joint Ventures ' refers to the REIT's proportionate share of the financial position and results of operation of its investment in joint ventures, which are accounted for using the equity method under IFRS in the consolidated financial statements, are presented below using the proportionate consolidation method at the REIT's ownership percentage of the related investment. Management views this method as relevant in demonstrating the REIT's ability to manage the underlying economics of the related investments, including the financial performance and the extent to which the underlying assets are leveraged, which is an important component of risk management.
Article content
For the purpose of the proportionate consolidation, the initial investment of both partners in the joint ventures were considered as being equity investments as opposed to a combination of equity and loans and accordingly, the related proportionate consolidation balance sheet items were eliminated as well as the associated finance income and finance costs. As the loans to the joint ventures were considered equity for proportionate consolidation purposes, any impairment recorded on the loans in accordance with IFRS 9 has been reversed for MD&A purposes. As such, any impairment recorded for IFRS purposes results in a difference in equity when reconciling IFRS and proportionate consolidation reporting.
Article content
' Investment Properties Portfolio ' or ' IP Portfolio ' refers to the eight wholly owned properties of the REIT.
Article content
' Net Rental Income Adjusted for IFRIC 21 ' refers to Net Rental Income excluding property taxes recorded under IFRIC 21 rules.
Article content
' Net Rental Income ' or 'NRI' refers to the rental income plus operating cost recoveries income plus other property revenue, less property operating costs and other costs.
Article content
' Total Portfolio ' refers to the eight properties referred to as the IP Portfolio and the five properties of the REIT held in joint-ownership with other parties.
Article content
'Weighted average lease term' or 'WALT ' is a metric used to measure a property portfolio's risk of vacancy and refers to the average period in which all leases in a property or portfolio will expire. It is calculated as the sum of the percentages of rentable area multiplied by the number of years in each remaining lease term.
Article content
' Weighted Average number of Units ' refers to the mean of periodic values in the number of issued and outstanding Units over a specific reporting period.
Article content
2025
2024
2025
2024
Net loss attributable to the Trust
(including share of net earnings from investments in joint ventures)
1,972
(13,845)
1,972
(13,845)
Add/(Deduct):
Net change in fair value of investment properties
(4,743)
11,994
(4,743)
11,994
Net change in fair value of financial derivatives

405
405
Adjustment for property taxes accounted for under IFRIC 21
3,043
2,912
3,043
2,912
Net change in fair value of Exchangeable securities
(4)
(385)
(4)
(385)
Foreign exchange gain
(65)

(65)

Deferred income tax recoveries
(40)

(40)

Non-controlling interest
10
(38)
10
(38)
FFO
173
1,043
173
1,043
Add/(Deduct):
Non-cash effect of straight line rents
192
191
192
191
Cash effect of the rental guarantee
184
171
184
171
Amortization of transaction costs on mortgage loans
72
63
72
63
Capex

(720)

(720)
AFFO
621
748
621
748
FFO / Units (diluted) ($)
0.01
0.03
0.01
0.03
AFFO / Units (diluted) ($)
0.02
0.02
0.02
0.02
Article content
Overview – GAAP and Non-GAAP
Article content
The REIT has identified specific key performance indicators to measure the progress of its long-term objectives. These are set out below:
Article content
March 31, 2025
December 31, 2024
Operating metrics
IP Portfolio
Total Portfolio
IP Portfolio
Total Portfolio
Number of properties
8
13
8
13
Gross leasable area (sq. ft.)
1,117,830
1,541,469
1,117,830
1,541,469
Occupancy rate – end of period
47.1%
58.9%
47.7%
59.3%
Weighted average lease term
4.0 years
3.8 years
4.0 years
4.0 years
Average initial yield (1)
3.1%
15.9%
3.9%
4.7%
Capital management metrics
IP Portfolio
Total Portfolio
IP Portfolio
Total Portfolio
Available cash (3)
$5,331
$6,866
$6,249
$7,572
Fair value of investment properties (3)
$373,930
$502,500
$353,850
$476,579
Debt-to-gross book value (2)
51.3%
58.8%
52.3%
59.8%
Debt-to-gross book value, net of cash (2)
50.6%
58.3%
51.5%
59.2%
Weighted average loan term to maturity
2.7 years
2.4 years
3.0 years
2.7 years
Weighted average interest rate (2)
3.67%
3.43%
4.00%
4.12%
Interest coverage ratio (2)
0.8 x
0.8 x
0.8 x
1.1 x
(1) Calculated on annualized Net Rental Income (based on Net Rental Income for the year-to-date period).
(2) As defined in the section 'Non-GAAP Financial Measures and Other Financial Measures' in the Q1 MD&A.
(3) See the section 'Capital Management' in the Q1 MD&A for further discussion on the composition and usefulness of this metric.
Article content
Three months ended March 31,
Year ended March 31,
(thousands of $ except per Unit and other data)
2025
2024
2025
2024
Financial performance metrics
Rental revenue
4,238
4,631
4,238
4,631
Rental revenue – Total Portfolio (1)
6,541
6,757
6,541
6,757
Net rental income
155
912
155
912
Net rental income – Total Portfolio (1)
1,957
3,636
1,957
3,636
Net income, attributable to the Trust
1,922
(13,579)
1,922
(13,579)
Funds from Operations (FFO) (1) (2)
173
1,043
173
1,043
Adjusted Funds from Operations (AFFO) (1) (2)
621
748
621
748
FFO per Unit (diluted) (1) (2)
0.01
0.03
0.01
0.03
AFFO per Unit (diluted) (1) (2)
0.02
0.02
0.02
0.02
(1) See the section 'Non-GAAP Financial Measures ' in the Q1 MD&A for more information on the REIT's non-GAAP financial measures and reconciliations thereof.
(2) The reconciliation of FFO and AFFO to Net Income can be found under the section 'Non-GAAP Reconciliation (FFO and AFFO)' in the Q1 MD&A.
Article content
About Inovalis REIT
Article content
Inovalis REIT is a real estate investment trust listed on the Toronto Stock Exchange in Canada. It was founded in 2013 by Inovalis and invests in office properties in primary markets of France, Germany and Spain. It holds 12 assets. Inovalis REIT acquires (indirectly) real estate properties via CanCorpEurope, authorized Alternative Investment Fund (AIF) by the CSSF in Luxemburg, and managed by Inovalis S.A.
Article content
About Inovalis Group
Article content
Inovalis S.A. is a French Alternative Investment fund manager, authorized by the French Securities and Markets Authority (AMF) under AIFM laws. Inovalis S.A. and its subsidiaries (Advenis S.A., Advenis REIM) invest in and manage Real Estate Investment Trusts such as Inovalis REIT, open ended funds (SCPI) with stable real estate focus such as Eurovalys (for Germany) and Elialys (Southern Europe), Private Thematic Funds raised with Inovalis partners to invest in defined real estate strategies and direct Co-investments on specific assets.
Article content
Inovalis Group ( www.inovalis.com), founded in 1998 by Inovalis SA, is an established pan European real estate investment player with EUR 7 billion of AuM and with offices in all the world's major financial and economic centers in Paris, Luxembourg, Madrid, Frankfurt, Toronto and Dubai. The group is comprised of 300 professionals, providing Advisory, Fund, Asset and Property Management services in Real Estate as well as Wealth Management services.
Article content
Article content
Article content
Article content
For further information, please contact:
Article content
Article content
Article content

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Victory Square Technologies Reports 2024 Results: Revenue Growth, Strategic Investments, and Portfolio Progress
Victory Square Technologies Reports 2024 Results: Revenue Growth, Strategic Investments, and Portfolio Progress

Globe and Mail

time43 minutes ago

  • Globe and Mail

Victory Square Technologies Reports 2024 Results: Revenue Growth, Strategic Investments, and Portfolio Progress

Victory Square Reports $23 Million in Adjusted Revenue for 2024, Highlighting Portfolio Growth Vancouver, British Columbia--(Newsfile Corp. - June 30, 2025) - Victory Square Technologies Inc. (CSE: VST) (OTC Pink: VSQTF) ("Victory Square" or the "Company"), a venture builder that invests in and develops high-growth technology companies, is pleased to share a summary of key milestones and audited financial highlights for the year ended December 31, 2024. The Company delivered a year of meaningful progress across its portfolio, highlighted by record financial performance, strategic asset monetization, and accelerating growth in its healthcare investments. These results position Victory Square for continued execution, strong momentum and a clear vision for long-term shareholder value creation in 2025 and beyond. 2024 Financial and Strategic Highlights Adjusted Revenue: Victory Square generated approximately $23.0 million in adjusted revenue in 2024, up from $17.6 million in 2023. GAAP Revenue: $16.7 million in 2024, compared to $12.1 million in the prior year, representing a 39% year-over-year increase. Cost of Goods Sold (COGS): $10.4 million in 2024, compared to $6.6 million in 2023. Gross Margin: $6.4 million in 2024, compared to $5.5 million in 2023. Asset Monetization: Completed the sale of BlockX to Edge Total Intelligence Inc. (TSXV: CTRL) in Q3 2024 for $1.7 million in listed shares. Strong Balance Sheet: including $6.16 million in cash and marketable securities, providing ample resources to fuel future growth and pursue strategic initiatives. Please see SEDAR+ for the Company's condensed consolidated audited financial statements and MD&A for audited annual consolidated financial statements for the year ended December 31, 2024. Hydreight Technologies: A Scalable Health Platform Hydreight Technologies Inc. (TSXV: NURS), a digital health company incubated by Victory Square, continued to scale its mobile wellness and telehealth platform across the U.S., achieving: $16.0 million in GAAP revenue for FY2024, up 39% YoY, and $22.3 million in adjusted revenue, up 31% YoY. Q1 2025 revenue of $6.53 million, up 34% YoY, with positive net income and adjusted EBITDA of $163,000. National recognition including rankings on the Deloitte Technology Fast 50 (Canada, #9), Fast 500 (North America, #56), and Ranked #13 on the Americas' Fastest Growing Companies 2025 list. Expanded National Network: Hydreight's platform now supports a network of over 3,000 registered nurses and 200+ prescribing physicians, serving patients across all 50 U.S. states. In addition to its core clinical provider base, Hydreight powers 400+ direct-to-consumer (D2C) healthcare brands and multiple white-label wellness partners, enabled by its scalable, plug-and-play infrastructure. On December 31, 2024, Victory Square held a 64% stake in Hydreight and continues to support its platform expansion and growth across new healthcare verticals. Health Innovation: Strategic Initiatives in 2024-25 Victory Square deepened its commitment to digital health through several key initiatives: VSDHOne Platform: A national, plug-and-play infrastructure for launching compliant direct-to-consumer healthcare brands across all 50 U.S. states. $10M Health Accelerator: Designed to incubate and invest in digital health startups focused on areas like biomarker testing, peptides, tele-pharmacy, and longevity. Pet Health: Victory Square is evaluating the growing pet wellness sector, building on prior virtual care solutions for animals. Insu Therapeutics: Advancing Oral Insulin for Diabetes Care Another promising digital health holding in Victory Square's portfolio is Insu Therapeutics Inc., a biotechnology company developing a non-invasive, oral insulin tablet for people living with diabetes. Victory Square holds approximately 22.8% ownership in Insu, which originated from research at the University of British Columbia (UBC). Insu's tablet uses a buccal delivery system —absorbing insulin through the inner cheek-bypassing the digestive tract and mimicking the body's natural insulin absorption via the liver. Preclinical trials have demonstrated insulin uptake comparable to injections, with prolonged glucose control and improved liver targeting. This innovation addresses a global health need. According to the International Diabetes Federation, over 500 million people worldwide are living with diabetes as of 2021, with the number expected to rise to 783 million by 2045. The global diabetes therapeutics market is projected to reach USD $118 billion by 2032 (Source: Market Research Future, Key highlights from Insu's development roadmap: Filed U.S. and international patents covering its novel tablet formulation and delivery polymers. Pursuing an FDA 505(b)(2) regulatory pathway, aiming to reduce development costs and timelines. Planning first-in-human trials in 2026, following preclinical success. Exploring domestic insulin tablet manufacturing to increase supply chain resilience. Insu is led by a multidisciplinary team: Dr. Anubhav Pratap-Singh (CEO & Co-Inventor): UBC Professor with 100+ publications and 7+ patents. Ammad Shorbaji (COO): Former senior executive at Sanofi with 25 years of regulatory and commercial experience. Dr. Tom Elliott (Medical Director): A leading Canadian endocrinologist with extensive clinical and academic credentials. Insu's work has garnered national and international media attention, with coverage from CBC, Global News, and other major outlets. This growing visibility supports early awareness as the company moves toward commercialization. Victory Square believes Insu Therapeutics represents both a strong commercial opportunity and a mission-aligned investment aimed at improving global health outcomes. The Company continues to support Insu through its next phase of growth and development. Outlook for 2025 and Beyond Victory Square enters 2025 with a strengthened balance sheet, a growing healthcare ecosystem, and a pipeline of high-potential assets. The Company's focus for 2025 includes: Scaling adoption of VSDHOne and expanding digital health verticals. Supporting growth of Hydreight and advancing Insu's clinical roadmap. Monetizing additional assets where appropriate. Continuing investment in biotech, health, and scalable technology platforms. " 2024 was a pivotal year for Victory Square," said Shafin Diamond Tejani, CEO. "We strengthened our balance sheet, scaled promising platforms, and unlocked value across the portfolio. We're committed to supporting innovation and creating long-term value for our shareholders in 2025 and beyond." Victory Square thanks its shareholders for their continued support and looks forward to sharing additional updates throughout the year. Sign up to VST's official newsletter at On behalf of the Board of Directors "Shafin Diamond Tejani" Director and Chief Executive Officer Victory Square Technologies Inc. For further information about Victory Square, please contact: Investor Relations Contact — Abbey Vogt Email: ir@ Telephone: 604 283-9166 Peter Smyrniotis — Director Telephone: 604 283-9166 ABOUT VICTORY SQUARE TECHNOLOGIES INC. Victory Square is a Venture Builder that provides investors a liquid way to invest in early-stage technology companies without buying a venture fund that requires accredited investor status or multi-year commitments. A diverse portfolio of 25+ innovative companies from around the world (founders come from: Ireland, Sri Lanka, Bulgaria, Australia, India, Brazil, the Middle East and North America) Sectors include: Digital Health, Artificial Intelligence (AI), Machine Learning (ML), Blockchain/Web3, Virtual & Augmented Reality (VR/AR), Gaming, Climate Tech Owner-operated (approx. 15% Management Ownership) Business Model: The Victory Square business model is to buy, build and invest in early stage tech companies. We spend upwards of 48 months with those companies until they're ready to spin-off or stand on their own. There are a couple of unique elements to our business model… We have unparalleled access to startups through our internal incubator and International network with over 250+ founders, investors, tech accelerators and venture capital firms from more than 60 countries. Second, our management team and advisors are actively involved in our investments from incubation through monetization, providing them with financial, operational, and strategic support to scale globally. We drive value by monetizing investments and reinvesting the gains in new innovations. The strategy was to build a self-sustaining business. VST is a publicly-traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6) and the OTC Pink (VSQTF). For more information, please visit Forward-Looking Information This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is generally identifiable by use of the words "believes," "may," "plans," "will," "anticipates," "intends," "could," "estimates," "expects," "forecasts," "projects" and similar expressions, and the negative of such expressions. All statements other than statements of historical facts contained in this news release are forward looking statements. Forward-looking information in this news release includes, without limitation, statements regarding the future plans and objectives of the Company, execution of business strategy, future performance and future growth, business prospects, synergies and opportunities of the Company and its related subsidiaries, and other factors beyond the Company's control. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the Company's actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information. Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances at the date such statements are made, including, but not limited to the Company being able to capitalize on the acquired assets, the ability of acquired assets to maintain its value as presently contemplated, the synergies of the acquired assets with the Company's operations, and such other assumptions presented in the Company's disclosure record. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. All forward-looking information herein is qualified in its entirety by this cautionary statement, and GameOn disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Use of Non-GAAP Financial Measures This release contains references to non-GAAP financial measures Adjusted Revenue and Adjusted EBITDA. The Company defines Adjusted Revenue as gross cash income before adjustments for the deferred portion of business partner setup, license, and sponsorship fees and gross and accrued receipts from blockchain grant funding. The Company defines Adjusted EBITDA as net income (loss) before interest, taxes, depreciation and amortization and before (i) transaction, restructuring, and integration costs and share-based payments expense, and (iii) gains/losses that are not reflective of ongoing operating performance including inventory impairment. The Company believes that the measure provides useful information to its shareholders and investors in understanding the Company's 2023 operating cash flow and may assist in the evaluation of the Company's business relative to that of its peers more accurately than GAAP financial measures alone. This data is furnished to provide additional information and does not have any standardized meaning prescribed by GAAP. Accordingly, it should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP and is not necessarily indicative of other metrics presented in accordance with GAAP.

Mogo Announces Results of its Annual General Meeting of Shareholders
Mogo Announces Results of its Annual General Meeting of Shareholders

Globe and Mail

time2 hours ago

  • Globe and Mail

Mogo Announces Results of its Annual General Meeting of Shareholders

The annual general meeting of shareholders (the "Meeting") of Mogo Inc. (NASDAQ: MOGO) (TSX: MOGO;) ("Mogo" or the "Company"), a digital wealth and payments business, was held today via live audiocast online and the Company is pleased to announce that all resolutions put forward, being the election of directors, the appointment of the auditors of the Company, and the renewal of the Company's stock option plan and all unallocated options thereunder, were approved. Each of the matters voted upon at the Meeting is discussed in detail in the Company's management information circular dated June 4, 2025 (the 'Circular'), which can be found under the Company's profile on SEDAR+ ( The total number of votes cast by shareholders by proxy or online at the Meeting was 9,529,647 votes, representing 38.94% of the Company's outstanding shares as at May 23, 2025. The voting results are detailed below. Election of Directors The nominees listed in the Circular were elected as directors of Mogo. Detailed results of the vote are as follows: Name of Nominee Votes For % Votes For Votes Withheld % Votes Withheld David Feller 6,744,975 97.55 169,436 2.45 Gregory Feller 6,744,490 97.54 169,921 2.46 Alex Shan 5,947,760 86.02 966,651 13.98 Christopher Payne 4,720,033 68.26 2,194,378 31.74 Kees van Winters 4,709,670 68.11 2,204,742 31.89 Kristin McAlister 4,710,470 68.13 2,203,942 31.87 Appointment of Auditor MNP LLP was re-appointed as auditor of the Company until the next annual general meeting of shareholders of the Company at remuneration to be fixed by the Company's board of directors. Detailed results of the vote are as follows: Votes For % Votes For Votes Withheld % Votes Withheld 9,496,273 99.65 33,373 0.35 Approval of Unallocated Options The Company's Stock Option Plan and all unallocated options under the Company's Stock Option Plan were renewed. Detailed results of the vote are as follows: Votes For % Votes For Votes Against % Votes Against 5,384,086 77.87 1,530,325 22.13 The Company has filed a report of voting results on all resolutions voted upon at the Meeting under its profile on SEDAR+ at About Mogo Mogo Inc. (NASDAQ:MOGO; TSX:MOGO) is a financial technology company with three distinct business lines: wealth, lending, and payments. Our mission is to provide consumers with innovative financial solutions that drive long-term financial health and success. We operate with a differentiated approach in each business, leveraging technology, behavioral science, and financial tools to create unique value propositions in our respective markets. Our wealth and lending businesses are focused on the Canadian market, where we are the only subprime consumer lender that also offers a holistic wealth and investing solution. This unique integration is designed to help consumers transition from borrowing and debt to long-term wealth building. Separately, our payments business is operated through Carta Worldwide, a wholly owned subsidiary that provides modern card issuing and processing solutions, primarily in Europe.

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights
Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

National Post

time3 hours ago

  • National Post

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Article content Article content – Dosing is underway in the Phase 3 CYB003 PARADIGM program which comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE™) and a long-term extension study (EXTEND), with anticipated combined enrollment of approximately 550 patients 1 – Article content Article content – Strengthened commercial preparations and manufacturing capabilities through partnerships with Osmind and Thermo Fisher Scientific, respectively – Article content – APPROACH expects to enroll 220 participants at approximately 45 clinical sites across Article content the United States 1 – Article content – Initiation of second CYB003 pivotal study EMBRACE and completion of CYB004 Phase 2 study in general anxiety disorder expected around mid-2025 1 – Article content – Cash totaled C$135 million as of March 31, 2025 – Article content This news release constitutes a 'designated news release' for the purposes of Cybin's prospectus supplement dated February 10, 2025, to its short form base shelf prospectus dated August 17, 2023, as amended December 22, 2023, April 8, 2024, and January 6, 2025. Article content TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported audited financial results for its fiscal year ended March 31, 2025, and recent business highlights. Article content 'During the past 12 months, we have continued to focus on building out the strong foundation that underpins the clinical and regulatory milestones we anticipate in the coming year,' said Doug Drysdale, Chief Executive Officer of Cybin. 'Heartened by U.S. Food and Drug Administration Commissioner Dr. Martin Makary's recent comments in support of prioritizing this innovative scientific work, as well as the burgeoning government and media attention the field is receiving, we remain steadfastly committed to advancing our two lead programs, CYB003 and CYB004, toward potential approval and commercialization.' Article content 'Developing novel therapies to address the unmet need in mental health care requires dedication, scientific rigor, and the integration of expertise across domains. To help us accelerate our clinical goals, we have entered into several strategic collaborations, including with Osmind and Thermo Fisher Scientific, and have formed strategic partnership agreements among our clinical trial sites. In this way, we leverage the competencies, resources, and infrastructures of these key stakeholders with a goal of expediting the development pathway. Cybin's lead clinical programs – CYB003, our Phase 3 pivotal program for the adjunctive treatment of major depressive disorder, and CYB004, our Phase 2 program in generalized anxiety disorder – continue to advance, and we look forward to sharing future updates.' Article content Recent Business and Pipeline Highlights: Article content The SPAs are designed to facilitate collaboration among sites, cultivate long-term partnerships, enhance efficiency in trial operations, and improve overall site performance. Article content Engaged Thermo Fisher Scientific, a world-class manufacturing partner, to provide U.S.-based manufacturing for the CYB003 program. Article content Thermo Fisher Scientific offers leading Contract Development and Manufacturing Organization services and has a successful track record across the manufacturing spectrum. Cybin broadened its existing strong relationship with Thermo Fisher Scientific to include the development of both the drug substance and drug product capsules for CYB003. Cybin has engaged Thermo Fisher Scientific as its manufacturing partner in the United States, including partnering with Thermo Fisher Scientific's pharma services sites in Florence, South Carolina, for Phase 3 clinical supply and future commercialization, and Cincinnati, Ohio, for Phase 3 capsule production. Article content Partnered with Osmind, a leading service provider to psychiatry practices in the U.S., with the objective of accelerating commercial preparation for clinical-stage pipeline. Article content Osmind advances psychiatry through technology and services to bring innovative mental health treatments to patients in need. Cybin expects to leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support commercial preparation for its clinical-stage pipeline. Article content Strengthened intellectual property portfolio with two additional U.S. patents in support of lead clinical programs CYB003 and CYB004. Article content To-date, Cybin's growing intellectual property portfolio comprises more than 90 granted patents and over 230 pending applications. The recently issued patents are as follows: Article content U.S. patent 12,291,499 includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041. U.S. patent 12,318,477 is expected to provide exclusivity until 2040 and includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular injection, including CYB004. Article content Clinical Program Update Article content CYB003: Summary of Phase 2 12-Month Efficacy Data in MDD Patients Article content 100% of participants receiving two doses of 16 mg were responders. 71% of participants receiving two doses of 16 mg were in remission. Mean change from baseline in MADRS was approximately -23 points after two 16 mg doses. Article content CYB004: Phase 2 proof-of-concept study in generalized anxiety disorder ('GAD') is underway Article content The Phase 2 study is a randomized, double-blind study evaluating the safety and efficacy of CYB004 in participants with GAD, with concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed. The Phase 2 study is being conducted at sites in the U.S. and is expected to complete around mid-2025. 1 Article content Q4 and Fiscal-Year 2025 Financial Highlights Article content Cash totaled C$135 million as of March 31, 2025. Net loss was C$31 million for the quarter ended March 31, 2025, compared to a net loss of C$21 million in the same period last year. Net loss was C$113 million for the year ended March 31, 2025, compared to a net loss of C$78 million in the same period last year. Cash-based operating expenses consisting of research, general, and administrative costs totaled C$31 million for the quarter ended March 31, 2025, compared to C$24 million, in the same period last year. Cash-based operating expenses consisting of research, general, and administrative costs totaled C$100 million for the year ended March 31, 2025, compared to C$65 million, in the same period last year. Cash flows used in operating activities were C$21 million for the quarter ended March 31, 2025, compared to C$21 million in the same period last year. Cash flows used in operating activities were C$101 million for the year ended March 31, 2025, compared to C$69 million in the same period last year. Article content About Cybin Article content Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Article content With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Article content Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Article content Notes: Article content There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See 'Cautionary Notes and Forward-Looking Statements'. Article content Cautionary Notes and Forward-Looking Statements Article content Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to complete its Phase 2 study for CYB004 around mid-year 2025; the ability of the Company to enroll participants and add additional clinical sites for the PARADIGM program; the Company's expectation to enroll 220 participants at approximately 45 clinical sites across the United States for the APPROACH study; initiation of EMBRACE study around mid-year 2025; the anticipated approval and commercialization of CYB003 and CYB004; the ability to accelerate commercial preparation of clinical-stage programs through the Company's partnership with Osmind; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. Article content These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the year ended March 31, 2025 and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Article content Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Article content Article content Article content Article content Contacts Article content Investor & Media Contact: Article content Article content Gabriel Fahel Article content Article content Chief Legal Officer Article content Article content Cybin Inc. Article content Article content Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store